Nivolumab Biosimilar - Research Grade

Nivolumab Biosimilar - Research Grade, Host: Humanized, IgG4 kappa

Target: PD-1.

Specificity: Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Nivolumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Nivolumab biosimilar is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• Artikelnummer: ICH4009-5MG
• Hersteller: Ichorbio
• Hersteller Artikelnummer: ICH4009-5MG
• Verpackungseinheit: 5mg
• Mengeneinheit: STK
• Reaktivität: Human
• Klonalität: Monoclonal
• Isotyp: IgG4 kappa
• Wirt: Humanized